Clinical Trial Update: 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating 89Zr-Panitumumab as an imaging agent to detect suspected metastatic lesions on 18F-FDG PET/CT in head and neck squamous cell carcinoma,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• 89Zr-Panitumumab (panitumumab labeled with zirconium-89)

Snippet

Sponsor: Stanford University | Conditions: Head-and-neck Squamous Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING